Introduction
============

Breast reconstruction and augmentation are frequently performed surgical procedures worldwide due to the high prevalence of breast cancer ([@b1-mmr-19-05-4271]) and cosmetic demand. Autologous fat transfer to the subcutaneous tissue is the most commonly used technique in these plastic and reconstructive surgical procedures as it appears to be relatively inexpensive, readily obtainable, safe and complication-free compared with artificial implants ([@b2-mmr-19-05-4271]). However, the long-term replacement outcomes may not be satisfactory, which may be, in part, attributed to low graft survival and poor vascularization ([@b3-mmr-19-05-4271]). Therefore, it is necessary to further improve the autologous fat grafting technique to overcome the above limitations.

Human adipose-derived stem cells (HASCs) are a population of pluripotent cells, which have a high proliferation capacity, possess preferential potential to differentiate into adipocytes and can secrete angiogenic growth factors. Therefore, the addition of HASCs to lipoaspirate may prevent graft volume loss and enhance blood vessel generation in the grafts. This hypothesis has been confirmed in previous clinical trials ([@b4-mmr-19-05-4271]--[@b6-mmr-19-05-4271]). However, the use of autologous HASCs has not been Food and Drug Administration-approved; this may be due to the fact that the reconstructive mechanism of HASCs remains to be fully elucidated. Therefore, it is essential to investigate the molecular mechanisms that induce the transition of HASCs towards adipocytes and attempt to develop a more effective combination to improve the efficacy of HASC therapy for breast reconstruction and augmentation ([@b7-mmr-19-05-4271]).

Currently, several genes have been identified to be associated with adipogenesis for HASCs. Cytokine interleukin-1α (IL-1α) is demonstrated to evidently inhibit the proliferation and adipogenic differentiation of HASCs through the activation of nuclear factor (NF)-κB and extracellular signal-regulated kinase 1/2 pathways; and subsequent upregulation of pro-inflammatory cytokines, including interleukin (IL)-8, IL-6, C-C motif chemokine ligand 2 and IL-1β, in adipose-derived stem cells ([@b8-mmr-19-05-4271]). A study by Strong *et al* ([@b9-mmr-19-05-4271]) analyzed the overall cytokine profile of HASCs undergoing adipogenic differentiation and also found a decrease in the expression of IL-1, but reported increases in IL-12, IL-17 and intercellular adhesion molecule-1. By transcriptome profile analysis, Satish *et al* ([@b10-mmr-19-05-4271]) identified several novel genes and signaling pathways involved in regulating adipogenesis, including periostin, protein phosphatase 1 regulatory inhibitor subunit 1A and fibroblast growth factor 11. MicroRNAs (miRNAs) are a class of small RNAs that are important for the regulation of cellular processes by downregulating gene expression via binding to the 3′-untranslated region. There is also evidence to indicate the roles of miRNAs in adipogenic differentiation. The levels of miRNA (miR)-27a and miR-27b have been found to be downregulated following the adipogenic induction of HASCs. The overexpression of miR-27a or miR-27b inhibits adipocyte differentiation by downregulating the expression of prohibitin; and the target association between miR-27a/b and prohibitin was confirmed using a luciferase reporter assay ([@b11-mmr-19-05-4271]). miR-17-5p and miR-106a were shown to promote the adipogenic lineage commitment of HASCs by directly targeting bone morphogenetic protein 2 and subsequently increasing adipogenic CCAAT enhancer binding protein α (C/EBPα) and peroxisome proliferator activated receptor (PPAR)γ ([@b12-mmr-19-05-4271]). In addition to miRNAs, long non-coding RNAs (lncRNAs) have emerged as important factors contributing to adipocyte differentiation in HASCs. Nuermaimaiti *et al* ([@b13-mmr-19-05-4271]) demonstrated that the knockdown of HOXA11-AS1 inhibited adipocyte differentiation, leading to the suppression of adipogenic-related gene transcription in addition to decreased lipid accumulation in HASCs. The knockdown of MIR31HG also inhibited adipocyte differentiation, whereas the overexpression of MIR31HG promoted adipogenesis *in vitro* and *in vivo* ([@b14-mmr-19-05-4271]). However, the adipogenic differentiation-related genes, miRNAs and lncRNAs of HASCs have received limited investigation.

Several scholars have put forward the competing endogenous RNAs (ceRNAs) hypothesis as an lncRNA-miRNA-mRNA link: LncRNAs may serve as molecular sponges for miRNAs and functionally liberate mRNA-targeted regulated by the aforementioned active miRNAs. Certain adipocyte differentiation-related lncRNA-miRNA-mRNA interaction axes have previously been obtained in bone marrow mesenchymal stem cells (BMSCs) ([@b15-mmr-19-05-4271],[@b16-mmr-19-05-4271]), but not in HASCs.

The aim of the present study was to screen crucial miRNAs, lncRNAs and mRNAs associated with the adipocyte differentiation of HASCs by constructing the miRNA-lncRNA-mRNA ceRNA regulatory network using microarray data collected from a public database. The results of the present study may improve current understanding of the molecular mechanisms that induce the transition of HASCs towards adipocytes and provide targets for inducing adipogenic differentiation.

Materials and methods
=====================

### Gene Expression Omnibus (GEO) dataset

The lncRNA, miRNA and mRNA expression profiles of HASCs prior to and following adipocyte differentiation were retrieved from the public GEO database (<http://www.ncbi.nlm.nih.gov/geo/>) under accession nos. GSE57593, GSE25715 and GSE61302 ([@b10-mmr-19-05-4271]), respectively. The GSE57593 microarray dataset (platform: GPL18109, Agilent-038314 CBC Homo sapiens lncRNA + mRNA microarray V2.0) included samples from four undifferentiated HASCs and six differentiated adipocyte cells, which were induced following adipogenic medium culture for 3 and 6 days, with three replicates of each. The GSE25715 non-coding RNA sequencing dataset (platform: GPL9442, AB SOLiD System 3.0, Homo sapiens), included samples from four undifferentiated HASCs \[two with adapter set A (from the 5′ to the 3′ end) and two with adapter set B (from the 3′ to the 5′ end)\] and eight adipocyte differentiated cells that were induced using adipogenic medium for 3 and 8 days, with two replicates of each and using adapter sets A and B. The GSE61302 microarray dataset (platform: GPL570, Affymetrix Human Genome U133 Plus 2.0 Array) included samples from five undifferentiated HASCs and 10 differentiated adipocyte cells which were induced with adipogenic medium for 7 days (four replicates) and 21 days (six replicates).

### Data preprocessing and differential expression analysis

For the microarray data, the raw data were preprocessed using the Robust Multichip Average algorithm ([@b17-mmr-19-05-4271]) as implemented in the Bioconductor R package (version 3.4.1; <http://www.bioconductor.org/packages/release/bioc/html/affy.html>), including background correction, quantile normalization and median summarization. For the sequencing data, low expression value data (=0, 70%) were filtered.

In consideration of the different differentiated time, the present study only focused on the differentially expressed genes (DEGs), lncRNAs (DELs) and miRNAs (DEMs) between the undifferentiated and differentiated cells. The DEGs, DELs and DEMs were identified using the Linear Models for Microarray data method ([@b18-mmr-19-05-4271]) in the Bioconductor R package (version 3.4.1; <http://www.bioconductor.org/packages/release/bioc/html/limma.html>). The empirical Bayes t-test was used to calculate the p-value, which was subsequently adjusted by the Benjamini-Hochberg (BH) procedure ([@b19-mmr-19-05-4271]). Genes were considered differentially expressed if they met the following conditions: P-value (adjusted) P\<0.05 and \|logFC(fold change)\| \>1 (that is, FC\>2). A hierarchical cluster heatmap was created using the R package pheatmap (version: 1.0.8; <http://cran.r-project.org/web/packages/pheatmap>) based on the Euclidean distance to observe the ability of the DEGs, DELs and DEMs to distinguish the differentiated from the undifferentiated samples.

### Protein-protein interaction (PPI) network

To screen crucial genes, the DEGs were imported into PPI data that were collected from the Search Tool for the Retrieval of Interacting Genes (version 10.0; [http://string db.org/](http://string db.org/)) database ([@b20-mmr-19-05-4271]). The PPIs with combined scores ≥0.4 (medium confidence) were selected to construct the PPI network, which was visualized using Cytoscape software (version 3.4; [www.cytoscape.org/](www.cytoscape.org/)) ([@b21-mmr-19-05-4271]). The network topological features, including the degree (number of interactions per node or protein), betweenness (number of shortest paths that pass through each node), and closeness centrality (average length of the shortest paths to access all other proteins in the network) were determined using the CytoNCA plugin in Cytoscape software (<http://apps.cytoscape.org/apps/cytonca>) ([@b22-mmr-19-05-4271]) to rank the nodes in the PPI network and screen hub genes. Modules were identified to be significant with an Molecular Complex Detection (MCODE) score ≥4 and ≥6 nodes.

Furthermore, the MCODE (version:1.4.2, <http://apps.cytoscape.org/apps/mcode>) plugin of Cytoscape software was also used to identify functionally related and highly interconnected modules from the PPI network with a degree cut-off of 2, node score cut-off of 0.2, k-core of 2 and maximum depth of 100 ([@b23-mmr-19-05-4271]).

### ceRNA regulatory network construction

The DEM-related target genes were predicted using the miRWalk database (version 2.0; <http://www.zmf.umm.uni-heidelberg.de/apps/zmf/mirwalk2>) ([@b24-mmr-19-05-4271]), which provides the largest collection of predicted and experimentally verified miR-target interactions with various miRNA databases, including miRWalk, miRanda, miRDB, miRMap, RNA22 and TargetScan. The miRNA-target gene interaction pairs were selected if they were predicted in at least five databases. The target genes were then overlapped with the DEGs to screen the DEM (upregulated)-DEG (downregulated) or DEM (downregulated)-DEG (upregulated) interaction pairs.

The miRWalk (version 2.0; <http://www.zmf.umm.uni-heidelberg.de/apps/zmf/mirwalk2>) ([@b24-mmr-19-05-4271]) and lnCeDB (<http://gyanxet-beta.com/lncedb/>) ([@b25-mmr-19-05-4271]) databases were used to screen the interactions between DELs and DEMs. The DEL (upregulated)-DEM (downregulated) and DEL (downregulated)-DEM (upregulated) interaction pairs were collected.

The DEL-DEM and DEM-DEG interactions were integrated to construct the lncRNA-miRNA-mRNA ceRNA network, which was visualized using Cytoscape software (version 3.4; [www.cytoscape.org/](www.cytoscape.org/)) ([@b21-mmr-19-05-4271]).

### Function enrichment analysis

Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were performed using the clusterProfiler tool (version 3.2.11; <http://www.bioconductor.org/packages/release/bioc/html/clusterProfiler.html>) to reveal the function of the DEGs in the PPI and the target genes of miRNAs. Adjusted P\<0.05 using the BH method was set as the cut-off value ([@b19-mmr-19-05-4271]).

Results
=======

### Differential expression analysis

Based on the given threshold (adjusted P\<0.05 and \|logFC\| \>1), a total of 925 DEGs were identified from 20,514 mRNAs between the undifferentiated HASCs and differentiated adipocyte cells, including 302 upregulated and 623 downregulated DEGs; 577 DELs were screened from 7,882 lncRNAs between the undifferentiated HASCs and differentiated adipocyte cells, including 323 upregulated and 254 downregulated DELs. A total of 35 DEMs were screened from 499 miRNAs between the undifferentiated HASCs and differentiated adipocyte cells (including 20 upregulated and 15 downregulated), based on the threshold of P\<0.05 and \|logFC\| \>1. The top 20 DEGs, DEMs and DELs are shown in [Table I](#tI-mmr-19-05-4271){ref-type="table"}. The heatmap indicated that these DEGs ([Fig. 1A](#f1-mmr-19-05-4271){ref-type="fig"}), DEMs ([Fig. 1B](#f1-mmr-19-05-4271){ref-type="fig"}) and DELs ([Fig. 1C](#f1-mmr-19-05-4271){ref-type="fig"}) distinguished the differentiated from the undifferentiated samples.

### PPI network analysis of DEGs to screen hub genes

A PPI network was constructed using the screened DEGs, which included 360 nodes (162 upregulated and 198 downregulated) and 1,381 interaction pairs ([Fig. 2](#f2-mmr-19-05-4271){ref-type="fig"}). According to the rank of three topological features, JUN, cyclin B1 (CCNB1), C-X-C motif chemokine ligand 10 (CXCL10), enolase 2 (ENO2), enoyl-CoA hydratase and 3-hydroxyacyl CoA dehydrogenase (EHHADH), protein tyrosine phosphatase, receptor type C (PTPRC), Rac family small GTPase 2 (RAC2), leptin (LEP) and kinase insert domain receptor (KDR) were considered as hub genes in the PPI network ([Table II](#tII-mmr-19-05-4271){ref-type="table"}). Six significant functionally related and highly interconnected modules were extracted from the whole PPI network ([Fig. 3](#f3-mmr-19-05-4271){ref-type="fig"}; [Table III](#tIII-mmr-19-05-4271){ref-type="table"}). Hub gene CCNB1 was enriched in module 1, which was associated with cell cycle ([Fig. 3A](#f3-mmr-19-05-4271){ref-type="fig"}). Hub gene CXCL10 was enriched in module 2 ([Fig. 3B](#f3-mmr-19-05-4271){ref-type="fig"}), which was associated with several inflammation pathways, including the chemokine signaling pathway, cytokine-cytokine receptor interaction, IL-17 signaling pathway, and tumor necrosis factor (TNF) signaling pathway. Hub gene ENO2 and PTPRC were respectively enriched into module 3 ([Fig. 3C](#f3-mmr-19-05-4271){ref-type="fig"}) and 4 ([Fig. 3D](#f3-mmr-19-05-4271){ref-type="fig"}). Hub gene JUN in module 4 was enriched in the NOD-like receptor signaling pathway or infection. Hub gene LEP in module 5 ([Fig. 3E](#f3-mmr-19-05-4271){ref-type="fig"}) was important in the Janus kinase (JAK)-signal transducer and activator of transcription (STAT) signaling pathway. Hub gene EHHADH in module 6 ([Fig. 3F](#f3-mmr-19-05-4271){ref-type="fig"}) was amino acid- or glucose metabolism-related ([Table IV](#tIV-mmr-19-05-4271){ref-type="table"}; [Fig. 4A](#f4-mmr-19-05-4271){ref-type="fig"}). As hub gene PTPRC and ENO2 were respectively enriched into module 4 and 3, but they were not included in the pathway-related genes, GO enrichment analysis was also performed. As a result, PTPRC was predicted to be involved in positive regulation of cytosolic calcium ion concentration ([Table V](#tV-mmr-19-05-4271){ref-type="table"}; [Fig. 4B](#f4-mmr-19-05-4271){ref-type="fig"}). The function of ENO2 was not predicted.

### DEM-DEG regulatory association analysis

A total of 7,381 target genes were predicted for the 21 upregulated DEMs, and 5,841 were predicted for the 15 downregulated DEMs. Following overlapping with the DEGs, 654 interactions were obtained for the 21 upregulated DEMs and 247 downregulated DEGs, and 197 interactions were obtained for the 14 downregulated DEMs and 96 upregulated DEGs.

The target genes of five upregulated DEMs (hsa-miR-103a-2-5p, hsa-miR-582-5p, hsa-miR-642a-5p, hsa-miR-1292-5p and hsa-miR-30c-5p and) were enriched into 29 KEGG pathways, whereas 36 KEGG pathways were enriched for six downregulated DEMs (hsa-miR-302d-3p, hsa-miR-154-3p, hsa-miR-485-3p, hsa-miR-25-5p, hsa-miR-487a and hsa-miR-411-3p) ([Fig. 5A](#f5-mmr-19-05-4271){ref-type="fig"}). Among them, hsa-miR-302d-3p regulated hub gene LEP to be involved in neuroactive ligand-receptor interaction; whereas hsa-miR-487a targeted hub gene EHHADH for involvement in amino acid (β-alanine, lysine, valine, leucine and isoleucine) metabolism; hub gene CXCL10 regulated by hsa-miR-411-3p was involved in the IL-17 signaling pathway, Toll-like receptor signaling pathway, and TNF signaling pathway ([Table VI](#tVI-mmr-19-05-4271){ref-type="table"}).

Furthermore, GO biological process term enrichment analysis was also performed to predict the functions of DEMs ([Fig. 5B](#f5-mmr-19-05-4271){ref-type="fig"}). As a result, GO terms were enriched for nine upregulated DEMs (hsa-miR-103-5p, hsa-let-7e-5p, hsa-miR-212-3p, hsa-miR-345-5p, hsa-miR-378a-5p, hsa-miR-642a-3p, hsa-miR-582-3p, hsa-miR-664a-3p and hsa-miR-668-3p) and five downregulated DEMs (hsa-miR-302d-3p, hsa-miR-485-3p, hsa-miR-130b-5p, hsa-miR-23a-5p and hsa-miR-23b-5p). hsa-miR-378a-5p may regulate hub gene RAC2 to be involved in cell-substrate adhesion. hsa-miR-130b-5p, hsa-miR-23a-5p and hsa-miR-302d-3p may regulate hub gene LEP to be involved in regulation of inflammatory response and IL-8 secretion ([Table VII](#tVII-mmr-19-05-4271){ref-type="table"}).

### ceRNA network

Using the miRWalk and InCeDB databases, 14 upregulated DEMs were predicted to regulate 60 downregulated DELs and nine downregulated DEMs were predicted to regulate 15 upregulated DELs. An lncRNA-miRNA-mRNA ceRNA network was subsequently established ([Fig. 6A and B](#f6-mmr-19-05-4271){ref-type="fig"}), in which 366 nodes (23 DEMs: 14 upregulated and nine downregulated; 268 DEGs: 67 upregulated and 201 downregulated; 75 DELs: 15 upregulated and 60 downregulated) and 560 interactions (450 DEL-DEM and 110 DEM-DEG) were present. In this ceRNA, upregulated RP11-552F3.9 (or RP11-15A1.7) may function as a ceRNA to respectively suppress the inhibitory effects of hsa-miR-23a-5p and hsa-miR-302d-3p (or hsa-miR-130b-5p) on LEP, resulting in its upregulated expression; whereas the downregulation of GDNF-AS1 may be insufficient to prevent the inhibitory effects of hsa-miR-378a-5p on hub gene RAC2, leading to its downregulated expression ([Fig. 6A and B](#f6-mmr-19-05-4271){ref-type="fig"}).

Discussion
==========

The present study aimed to identify crucial mRNAs, miRNAs and lncRNAs for the adipocyte differentiation of HASCs based on a series of bioinformatics analyses, including PPI network construction, module analysis, miRNA-mRNA regulatory pair prediction, ceRNA network generation and function enrichment. In these analyses, the LEP gene was enriched and was regulated by RP11-552F3.9 (or RP11-15A1.7)-hsa-miR-23a-5p/hsa-miR-302d-3p (or hsa-miR-130b-5p), and involved in the inflammatory response, indicating that the LEP-related ceRNA axis may be important for the differentiation of adipose tissue-derived stem cells into adipocytes.

There is evidence demonstrating that LEP is important in adipocyte differentiation ([@b26-mmr-19-05-4271]). Lee *et al* ([@b27-mmr-19-05-4271]) observed that leptin treatment can promote lipid droplet formation and adipocyte differentiation, which was evaluated by the activity of glycerol-3-phosphate dehydrogenase activity, of HASCs. Additionally, the effect of leptin on adipocyte differentiation was found to be higher for HASCs than BMSCs ([@b27-mmr-19-05-4271]). Another study indicated that, in BMSCs, leptin may accelerate osteogenic differentiation but inhibit adipocyte differentiation ([@b28-mmr-19-05-4271]). Similarly, leptin was shown to have a suppressive effect on adipogenesis in dental pulp stem cells and periodontal ligament stem cells ([@b29-mmr-19-05-4271]). These findings suggest that leptin may be a specific factor for regeneration of the subcutaneous fat layer using HASCs for tissue engineering. As expected, the LEP gene was also significantly upregulated in differentiated adipocyte samples compared with undifferentiated HASCs in the present study. It was predicted that the downstream of LEP may be involved in the JAK-STAT signaling pathway to mediate the inflammatory response via interaction with certain anti-inflammatory-related factors (IL4R, downregulated; [Table IV](#tIV-mmr-19-05-4271){ref-type="table"}; [Fig. 3E](#f3-mmr-19-05-4271){ref-type="fig"}). This prediction appears to have been indirectly verified by previous studies; it has been reported that leptin may have a promoting effect on the astroglial differentiation of stem cells through activation of the JAK-STAT pathway, with JAK-STAT inhibitors decreasing the expression of astrocyte marker leptin ([@b30-mmr-19-05-4271]). STAT6 is reported to inhibit human IL-4 promoter activity in T cells and downregulate the gene expression of IL-4 ([@b31-mmr-19-05-4271]). IL-4/IL4R can inhibit adipocyte differentiation by two mechanisms: Inhibiting adipogenesis via downregulating the expression of PPARγ and C/EBPα; and promoting lipolysis in mature adipocytes via enhancing the activity and translocation of hormone-sensitive lipase to decrease lipid deposits ([@b32-mmr-19-05-4271]). However, the LEP-JAK-STAT-IL-4/IL4R signal pathways in the adipocyte differentiation of HASCs requires further experimental validation. In addition to the downstream pathways, the present study also analyzed the upstream non-coding RNAs of LEP, including miRNAs and lncRNAs, which were previously considered to be crucial for the adipogenic differentiation of HASCs ([@b13-mmr-19-05-4271],[@b14-mmr-19-05-4271],[@b33-mmr-19-05-4271]--[@b36-mmr-19-05-4271]). The results identified the RP11-552F3.9 (or RP11-15A1.7)-hsa-miR-23a-5p/hsa-miR-302d-3p (or hsa-miR-130b-5p)-LEP ceRNA axes. miR-130 has been shown to affect adipocyte differentiation from preadipocytes, with overexpressing miR-130 impairing adipogenesis and reducing miR-130-enhanced adipogenesis, and its potential target may be adipogenesis-related gene PPARγ ([@b37-mmr-19-05-4271]). In addition, the inhibition of miR-23a has been reported to increase the adipogenic differentiation of BMSCs ([@b38-mmr-19-05-4271]). In line with these findings, the present study found that hsa-miR-130b-5p and has-miR-23a-5p were downregulated in adipocyte differentiated HASCs. There have been no reports on the roles of miR-302d-3p and the above lncRNAs (RP11-552F3.9 and RP11-15A1.7) for adipocyte differentiation, indicating they may be novel targets identified by the present study.

RAC2 was identified as another hub gene that may be involved in the adipocyte differentiation of HASCs by miRNA-mRNA regulatory pair prediction and ceRNA network analysis. RAC2 was related to cell-substrate adhesion. It is well accepted that cell-substrate adhesion can control the fate of stem cells ([@b39-mmr-19-05-4271]). A previous study showed that HASCs differentiated into adipocytes when the substrate stiffness decreased ([@b40-mmr-19-05-4271]). Focal adhesion kinase (FAK) is a central protein involved in cell-substrate adhesion by Cas-Rac-lamellipodin signaling ([@b41-mmr-19-05-4271]). The stimulation of Rac and increase in the activity of FAK enhanced cell tension by maintaining cell shape and matrix adhesion ([@b42-mmr-19-05-4271]), whereas reduced cell stiffness and reduced adhesion strength have been observed in FAK-deficient cells ([@b43-mmr-19-05-4271]). The inhibition of FAK has also been reported to lead to the elevation of adipogenic marker gene LEP and lipid accumulation in HASCs ([@b43-mmr-19-05-4271]). These findings implicate the underlying anti-adipogenic activity of FAK and RAC. In line with these findings, the present study found that RAC2 was downregulated in adipocyte differentiated HASCs. Furthermore, it was predicted that RAC2 may be regulated by GDNF-AS1-hsa-miR-378a-5p. Previous evidence has shown that miR-378 is an adipogenesis-related miRNA in human adipocytes ([@b44-mmr-19-05-4271]). The expression of miR-378a is upregulated in the adipose tissues of high fat diet-induced obese mice, and during the differentiation of preadipocytes ([@b45-mmr-19-05-4271],[@b46-mmr-19-05-4271]). Investigations of the mechanism have revealed that miR-378 may induce adipogenesis by targeting mitogen-activated protein kinase 1 ([@b45-mmr-19-05-4271]), E2F transcription factor 2 and Ras-related nuclear-binding protein 10 ([@b46-mmr-19-05-4271]). Accordingly, it was hypothesized that hsa-miR-378a-5p may be upregulated in adipocyte differentiated HASCs, which was demonstrated in the present study. However, further experiments are required to confirm the role of this miRNA in HASC differentiation and its targeted interactions with RAC2. There are no previous reports on the roles of GDNF-AS1 in HASC differentiation, indicating it may also be a novel target identified by the present study.

Hub genes CXCL10 in module 2 and EHHADH in module 6 were shown to be respectively regulated by hsa-miR-411-3p and hsa-miR-487a, being involved in inflammatory and amino acid metabolism pathways for HASC differentiation. As reported for LEP above, inflammation promotes the adipocyte differentiation of HASCs, whereas CXCL10 is a well-known pro-inflammatory chemokine ([@b47-mmr-19-05-4271]). Therefore, CXCL10 may be upregulated in adipocyte differentiated HASCs, which was confirmed in the present study. EHHADH has been reported as a downstream target upregulated by PPAR ([@b48-mmr-19-05-4271]). PPAR is an important marker in stimulating adipogenesis ([@b12-mmr-19-05-4271]). EHHADH may also be expressed at a high level in adipocyte differentiated HASCs, which was in consistent with the present study. These two miRNAs regulating CXCL10 and EHHADH have not been demonstrated to be responsible for HASC differentiation, which highlights potential directions in future investigations.

CCNB1, JUN and PTPRC were suggested to be important for adipocyte differentiation from HASCs according to the PPI network analysis. With reference to previous studies, high expression levels of CCNB1 ([@b49-mmr-19-05-4271]) and JUN ([@b50-mmr-19-05-4271]) may be positively associated with the proliferation of stem cells. Generally, the differentiation process can be executed only following weakening of the proliferation ability of stem cells. In the adipocyte differentiation of HASCs, CCNB1 and JUN may be downregulated, which was verified in the present study. PTPRC is also known as CD45, a JAK phosphatase, which negatively regulates cytokine receptor signaling via inhibiting the activity of STAT3 ([@b51-mmr-19-05-4271],[@b52-mmr-19-05-4271]). According to the findings of LEP above, PTPRC may be downregulated for the adipocyte differentiation of HASCs, which was in line with the results of the present study.

There were some limitations in the present study. First, adipocyte differentiated cells were induced following different culture durations in the GSE57593, GSE25715 and GSE61302 datasets, which may lead to differences in the expression levels of the identified mRNAs, miRNAs and lncRNAs if the same samples were used for their detection. Second, the sample size of each dataset (GSE57593: Four undifferentiated HASCs and six adipocyte differentiated cells; GSE25715: Four undifferentiated HASCs and eight adipocyte differentiated cells: GSE61302: Five undifferentiated HASCs and 10 adipocyte differentiated cells) was small. Additional high-throughput sequencing experiments with larger samples are required to confirm the conclusions. Third, the present study comprised preliminary screening; however, further wet experiments, including quantitative-polymerase chain reaction analysis, western blotting, dual luciferase reporter assays, and knockout or overexpression *in vitro* and *in vivo*, are indispensable to confirm the expression levels of the identified target genes and validate the regulatory associations between DEMs and DELs/DEGs.

In conclusion, the present study preliminarily identified several crucial DEGs (LEP, RAC2, CXCL10, EHHADH CCNB1, JUN and PTPRC), DEMs (has-miR-130b-5p and has-miR-23a-5p, has-miR-302d-3p, has-miR-378a-5p, hsa-miR-411-3p and hsa-miR-487a) and DELs (RP11-552F3.9, RP11-15A1.7 and GDNF-AS1) for inducing the adipogenic differentiation of HASCs. Among these, the RP11-552F3.9 (or RP11-15A1.7)-hsa-miR-302d-3p-LEP ceRNA interaction axes may be particularly important and represents a novel mechanism for the adipogenic differentiation of HASCs. Further *in vitro* and *in vivo* investigations are required to confirm their roles in breast reconstruction and augmentation.
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###### 

Top 10 upregulated and downregulated differentially expressed lncRNAs, miRNAs and mRNAs.

  lncRNAs         mRNAs    miRNAs                                                                      
  --------------- -------- ------------- ------------------ ------- ------------- ------------ ------- --------------
  ZBED3-AS1       4.74     2.74×10^−7^   hsa-miR-29b-2\*    2.89    3.08×10^−5^   FGF11        2.14    3.54×10^−7^
  RP11-95P13.1    4.95     5.72×10^−7^   hsa-miR-642a-3p    5.28    4.29×10^−4^   DDIT4L       3.38    4.11×10^−7^
  AC104654.2      4.12     1.08×10^−5^   hsa-miR-2114       2.80    1.31×10^−3^   PKP2         1.74    4.11×10^−7^
  RP11-196G18.3   2.19     1.41×10^−5^   hsa-miR-30a\*      2.54    2.20×10^−3^   GPR155       1.57    4.11×10^−7^
  RP11-439A17.9   2.19     1.41×10^−5^   hsa-miR-34b\*      4.57    3.85×10^−3^   ZNF582-AS1   1.20    4.11×10^−7^
  RP5-998N21.4    2.19     1.41×10^−5^   hsa-miR-668        2.29    4.38×10^−3^   PGRMC1       1.10    4.11×10^−7^
  CTC-564N23.2    4.65     2.62×10^−5^   hsa-miR-345        1.81    4.20×10^−3^   ZNF436-AS1   2.26    5.34×10^−7^
  CHL1-AS1        3.53     5.17×10^−5^   hsa-miR-675\*      2.60    5.68×10^−3^   FAM162A      1.14    5.34×10^−7^
  AC104653.1      2.94     5.17×10^−5^   hsa-miR-34a        3.54    8.48×10^−3^   BNIP3        1.23    1.44×10^−6^
  RP11-696N14.1   2.15     5.17×10^−5^   hsa-miR-378c       3.10    9.65×10^−3^   IGFBP5       1.74    1.85×10^−6^
  LINC01085       −4.82    1.20×10^−7^   hsa-miR-485-3p     −3.30   9.05×10^−4^   FOSB         −6.71   1.28×10^−14^
  APCDD1L-AS1     −3.14    2.45×10^−6^   hsa-miR-3151       −2.15   1.80×10^−3^   IER2         −1.72   2.51×10^−9^
  RP11-54A9.1     −3.45    5.73×10^−6^   hsa-miR-130b\*     −1.42   6.82×10^−3^   KLF2         −2.02   3.82×10^−9^
  CTD-2354A18.1   −3.16    7.55×10^−6^   hsa-miR-302d       −1.66   8.82×10^−3^   ID1          −4.29   1.64×10^−8^
  CTD-2066L21.2   −5.09    1.11×10^−5^   hsa-miR-487a       −2.39   7.82×10^−3^   SKIL         −1.49   4.79×10^−8^
  RP11-114H23.1   −1.83    1.11×10^−5^   hsa-miR-411\*      −1.31   4.96×10^−2^   PRIMA1       −2.89   9.17×10^−8^
  RP3-410C9.2     −5.035   1.30×10^−5^   hsa-miR-154\*      −2.12   1.72×10^−2^   RRM2         −4.51   9.17×10^−8^
  APOBEC3B-AS1    −3.97    1.30×10^−5^   hsa-let-7e         −1.35   2.81×10^−3^   EGR3         −5.27   9.17×10^−8^
  RP11-30P6.6     −3.10    1.41×10^−5^   hsa-miR-125b-1\*   −1.54   2.84×10^−2^   C16orf89     −2.88   1.73×10^−7^
  LINC00460       −3.07    2.39×10^−5^   hsa-miR-23b        −1.03   4.18×10^−2^   NFKBIZ       −1.84   2.89×10^−7^

lncRNA, long non-coding RNA; miRNA, microRNA.

###### 

Topological features of DEGs in the protein-protein interaction network.

  DEG      Degree   DEG       Betweenness   DEG      Closeness   Overlapped   Expression
  -------- -------- --------- ------------- -------- ----------- ------------ ------------
  JUN      52       JUN       31682.11      JUN      0.12        JUN          Down
  CCNB1    40       EHHADH    14484.48      PTPRC    0.12        CCNB1        Down
  CXCL10   33       RAC2      9452.98       ENO2     0.12        CXCL10       Up
  CCNB2    32       CCNB1     9055.00       CCNB1    0.12        ENO2         Up
  AURKA    31       TAC1      8899.64       RAC2     0.12        EHHADH       Up
  KIF11    31       ENO2      8383.99       KDR      0.12        PTPRC        Down
  ENO2     30       KDR       7498.68       VIM      0.12        RAC2         Down
  KIF2C    30       PTPRC     6640.64       EHHADH   0.12        LEP          UP
  EHHADH   29       PRKAR2B   6288.09       HPGDS    0.12        KDR          Down
  PTPRC    28       THBS1     5735.04       MCL1     0.12        ITGAM        Down
  HADH     28       VIM       4843.88       TAC1     0.12        ITGAX        Down
  RAC2     27       LEP       4442.09       CXCL10   0.11        CXCR4        Down
  CXCR4    27       CXCL10    4424.07       MGP      0.11        HADH         Up
  EZH2     27       HADH      4155.38       CXCR4    0.11        MGP          Down
  MCM2     25       MGP       3982.14       LEP      0.11        TAC1         Down
  PLK4     24       HPGDS     3752.53       BMP2     0.11                     
  CENPF    24       CNR1      3700.56       PTPRF    0.11                     
  CDCA8    24       PRKG2     3608.14       ADIPOQ   0.11                     
  LEP      23       CALB2     3569.40       WNT5A    0.11                     
  ITGAX    23       WNT5A     3556.75       ACE      0.11                     
  CXCL11   23       ITGAX     3251.43       ITGAM    0.11                     
  BLM      23       AK4       3154.06       THBS1    0.11                     
  KIF15    23       TUBA4A    2982.07       NES      0.11                     
  CDT1     23       HMOX1     2856.41       CPT1A    0.11                     
  KDR      22       PTPRF     2836.38       PLIN1    0.11                     
  MGP      22       ADIPOQ    2766.04       CX3CL1   0.11                     
  CCL28    22       ITGAM     2744.81       BTK      0.11                     
  HJURP    22       CXCR4     2674.93       MAP2K6   0.11                     
  TAC1     21       ITGA7     2632.36       CXCL2    0.11                     
  ITGAM    21       BMP2      2624.89       CXCL1    0.11                     
  CXCL2    21       PLIN1     2616.07       CALB2    0.11                     
  CXCL1    21       ACE       2575.42       ITGAX    0.11                     
  TUBA4A   20       ITGB2     2559.34       HADH     0.11                     
  MCM5     20       ALDH3A2   2510.02       IRF1     0.11                     
  MCL1     19       RRAD      2504.60       CCL28    0.11                     

DEG, differentially expressed gene.

###### 

Module analysis results.

  Cluster   Score^[a](#tfn3-mmr-19-05-4271){ref-type="table-fn"}^   Nodes (n)   Edges (n)   Node IDs
  --------- ------------------------------------------------------- ----------- ----------- --------------------------------------------------------------------------------------------------------------------------------------------
    1       17.89                                                   19          161         HELLS, EZH2, HJURP, CDT1, CENPF, MCM2, POLE2, FAM64A, SPAG5, KIF2C, BLM, PLK4, CDCA8, KIF14, AURKA, KIF11, KIF15, CCNB1, CCNB2
    2       13.00                                                   13          78          CXCL10, GAL, CXCL5, CXCL11, C5, P2RY12, CCL28, CNR1, S1PR1, CXCL2, CXCL1, CXCR4, CXCL6
    3       9.78                                                    10          44          GEN1, COMP, HADH, PTPRF, HRASLS5, ENO2, MCL1, MGP, EREG, NES
    4       7.00                                                    21          70          OAS1, JUN, GNRHR2, AVPR1A, P2RY1, ITGAM, CCL22, HERC5, EDNRB, OASL, PTGFR, IFIH1, PTPRC, IRF7, IFI44, HTR2A, ITGAX, TAC1, IFI6, NMB, HTR2B
    5       4.67                                                    10          21          ACSL1, SCD, DGAT2, PNPLA2, LEP, CIDEC, IL4R, IL10RA, TSLP, FABP4
    6       4.36                                                    12          24          TUBA1A, PRKAR2B, ABAT, EHHADH, ALDH3A2, TUBD1, ALDH1B1, MAPRE3, PECR, PDHX, TUBA4A, HSD11B1
    7       3.33                                                    4           5           PDE2A, PRELP, RRAD, LRRC2
    8       3.13                                                    17          25          MMRN1, ANK2, ATP1A2, NRCAM, VIM, KDR, ATP1A1, PLOD2, TIMP3, COL8A2, COL4A4, CALB2, PLN, KCNQ3, A2M, COL18A1, SCN2A
    9       3.00                                                    3           3           HIST1H3C, HIST1H2AC, HIST1H2BD
  10        3.00                                                    3           3           HSD17B14, ADH4, TP53I3
  11        3.00                                                    3           3           TRIM69, RNF19B, TRIM9
  12        3.00                                                    3           3           GPAT2, AGPAT5, GPD1
  13        3.00                                                    3           3           VLDLR, DAB1, MAP1B
  14        3.00                                                    3           3           LAMB3, ITGA7, LAMA2

Score = density × number of nodes.

###### 

Kyoto Encyclopedia of Genes and Genomes pathway enrichment for genes in modules.

  Cluster   ID         Description                                    Adjusted P-value   Genes
  --------- ---------- ---------------------------------------------- ------------------ ---------------------------------------------------
  1         hsa04914   Progesterone-mediated oocyte maturation        1.16×10^−3^        AURKA/CCNB1/CCNB2
  1         hsa04110   Cell cycle                                     1.16×10^−3^        MCM2/CCNB1/CCNB2
  1         hsa04114   Oocyte meiosis                                 1.16×10^−3^        AURKA/CCNB1/CCNB2
  1         hsa04068   FoxO signaling pathway                         1.16×10^−3^        PLK4/CCNB1/CCNB2
  1         hsa03030   DNA replication                                2.02×10^−3^        MCM2/POLE2
  1         hsa04115   p53 signaling pathway                          5.99×10^−3^        CCNB1/CCNB2
  1         hsa04218   Cellular senescence                            2.73×10^−2^        CCNB1/CCNB2
  2         hsa04062   Chemokine signaling pathway                    1.96×10^−9^        CXCL10/CXCL5/CXCL11/CCL28/CXCL2/CXCL1/CXCR4/CXCL6
  2         hsa04060   Cytokine-cytokine receptor interaction         2.03×10^−8^        CXCL10/CXCL5/CXCL11/CCL28/CXCL2/CXCL1/CXCR4/CXCL6
  2         hsa04657   IL-17 signaling pathway                        2.28×10^−6^        CXCL10/CXCL5/CXCL2/CXCL1/CXCL6
  2         hsa04668   TNF signaling pathway                          1.60×10^−4^        CXCL10/CXCL5/CXCL2/CXCL1
  2         hsa05133   Pertussis                                      1.41×10^−3^        CXCL5/C5/CXCL6
  2         hsa05323   Rheumatoid arthritis                           1.94×10^−3^        CXCL5/CXCL1/CXCL6
  2         hsa04672   Intestinal immune network for IgA production   1.28×10^−2^        CCL28/CXCR4
  2         hsa05134   Legionellosis                                  1.41×10^−2^        CXCL2/CXCL1
  2         hsa05132   Salmonella infection                           0.02.99×10^−2^     CXCL2/CXCL1
  2         hsa04620   Toll-like receptor signaling pathway           3.88×10^−2^        CXCL10/CXCL11
  4         hsa04080   Neuroactive ligand-receptor interaction        7.99×10^−4^        AVPR1A/P2RY1/EDNRB/PTGFR/HTR2A/HTR2B
  4         hsa04020   Calcium signaling pathway                      8.35×10^−4^        AVPR1A/EDNRB/PTGFR/HTR2A/HTR2B
  4         hsa05164   Influenza A                                    8.30×10^−3^        OAS1/JUN/IFIH1/IRF7
  4         hsa05168   Herpes simplex infection                       8.30×10^−3^        OAS1/JUN/IFIH1/IRF7
  4         hsa05162   Measles                                        3.60×10^−2^        OAS1/IFIH1/IRF7
  4         hsa05161   Hepatitis B                                    3.68×10^−2^        JUN/IFIH1/IRF7
  4         hsa04621   NOD-like receptor signaling pathway            4.88×10^−2^        OAS1/JUN/IRF7
  5         hsa04630   Jak-STAT signaling pathway                     6.39×10^−4^        LEP/IL4R/IL10RA/TSLP
  5         hsa03320   PPAR signaling pathway                         8.88×10^−4^        ACSL1/SCD/FABP4
  5         hsa04060   Cytokine-cytokine receptor interaction         1.57×10^−3^        LEP/IL4R/IL10RA/TSLP
  5         hsa01212   Fatty acid metabolism                          9.00×10^−3^        ACSL1/SCD
  5         hsa04923   Regulation of lipolysis in adipocytes          9.10×10^−3^        PNPLA2/FABP4
  5         hsa00561   Glycerolipid metabolism                        9.65×10^−3^        DGAT2/PNPLA2
  5         hsa04920   Adipocytokine signaling pathway                0.01.06×10^−2^     ACSL1/LEP
  5         hsa04152   AMPK signaling pathway                         2.76×10^−2^        SCD/LEP
  5         hsa00061   Fatty acid biosynthesis                        4.36×10^−2^        ACSL1
  6         hsa00410   β-alanine metabolism                           1.50×10^−6^        ABAT/EHHADH/ALDH3A2/ALDH1B1
  6         hsa00280   Valine, leucine and isoleucine degradation     4.60×10^−6^        ABAT/EHHADH/ALDH3A2/ALDH1B1
  6         hsa00380   Tryptophan metabolism                          1.65×10^−4^        EHHADH/ALDH3A2/ALDH1B1
  6         hsa00071   Fatty acid degradation                         1.66×10^−4^        EHHADH/ALDH3A2/ALDH1B1
  6         hsa00310   Lysine degradation                             3.22×10^−4^        EHHADH/ALDH3A2/ALDH1B1
  6         hsa00340   Histidine metabolism                           1.98×10^−3^        ALDH3A2/ALDH1B1
  6         hsa00053   Ascorbate and aldarate metabolism              2.21×10^−3^        ALDH3A2/ALDH1B1
  6         hsa00650   Butanoate metabolism                           2.21×10^−3^        ABAT/EHHADH
  6         hsa00640   Propanoate metabolism                          2.57×10^−3^        ABAT/EHHADH
  6         hsa00620   Pyruvate metabolism                            3.44×10^−3^        ALDH3A2/ALDH1B1
  6         hsa01212   Fatty acid metabolism                          4.70×10^−3^        EHHADH/PECR
  6         hsa00330   Arginine and proline metabolism                4.70×10^−3^        ALDH3A2/ALDH1B1
  6         hsa05130   Pathogenic *Escherichia coli* infection        5.24×10^−3^        TUBA1A/TUBA4A
  6         hsa00561   Glycerolipid metabolism                        6.00×10^−3^        ALDH3A2/ALDH1B1
  6         hsa00010   Glycolysis/Gluconeogenesis                     6.90×10^−3^        ALDH3A2/ALDH1B1
  6         hsa04146   Peroxisome                                     9.55×10^−3^        EHHADH/PECR
  6         hsa04540   Gap junction                                   1.01×10^−2^        TUBA1A/TUBA4A
  6         hsa04210   Apoptosis                                      2.27×10^−2^        TUBA1A/TUBA4A
  6         hsa04145   Phagosome                                      2.58×10^−2^        TUBA1A/TUBA4A
  6         hsa04530   Tight junction                                 3.03×10^−2^        TUBA1A/TUBA4A
  6         hsa01040   Biosynthesis of unsaturated fatty acids        4.23×10^−2^        PECR

###### 

GO enrichment for genes in modules.

  Cluster   ID           Description                                                  Adjusted P-value   Genes
  --------- ------------ ------------------------------------------------------------ ------------------ -------------------------------------------------------------------
  1         GO:0051310   Metaphase plate congression                                  4.09×10^−11^       CDT1/CENPF/SPAG5/KIF2C/CDCA8/KIF14/CCNB1
  1         GO:0051303   Establishment of chromosome localization                     1.45×10^−10^       CDT1/CENPF/SPAG5/KIF2C/CDCA8/KIF14/CCNB1
  1         GO:0050000   Chromosome localization                                      1.45×10^−10^       CDT1/CENPF/SPAG5/KIF2C/CDCA8/KIF14/CCNB1
  1         GO:0140014   Mitotic nuclear division                                     1.71×10^−10^       CDT1/CENPF/SPAG5/KIF2C/CDCA8/KIF14/AURKA/KIF11/CCNB1
  1         GO:0000280   Nuclear division                                             5.46×10^−9^        CDT1/CENPF/SPAG5/KIF2C/CDCA8/KIF14/AURKA/KIF11/CCNB1
  2         GO:0060326   Cell chemotaxis                                              9.21×10^−14^       CXCL10/CXCL5/CXCL11/C5/CCL28/S1PR1/CXCL2/CXCL1/CXCR4/CXCL6
  2         GO:0050900   Leukocyte migration                                          9.21×10^−14^       CXCL10/CXCL5/CXCL11/C5/P2RY12/CCL28/S1PR1/CXCL2/CXCL1/CXCR4/CXCL6
  2         GO:0002685   Regulation of leukocyte migration                            9.21×10^−14^       CXCL10/CXCL5/CXCL11/C5/P2RY12/CCL28/CXCL2/CXCL1/CXCL6
  2         GO:0050920   Regulation of chemotaxis                                     1.35×10^−13^       CXCL10/CXCL5/CXCL11/C5/S1PR1/CXCL2/CXCL1/CXCR4/CXCL6
  2         GO:0030595   Leukocyte chemotaxis                                         2.66×10^−13^       CXCL10/CXCL5/CXCL11/C5/S1PR1/CXCL2/CXCL1/CXCR4/CXCL6
  4         GO:0007204   Positive regulation of cytosolic calcium ion concentration   6.33×10^−7^        AVPR1A/P2RY1/EDNRB/PTPRC/HTR2A/TAC1/NMB/HTR2B
  4         GO:0009615   Response to virus                                            6.33×10^−7^        OAS1/CCL22/HERC5/OASL/IFIH1/PTPRC/IRF7/IFI44
  4         GO:0051480   Regulation of cytosolic calcium ion concentration            6.33×10^−7^        AVPR1A/P2RY1/EDNRB/PTPRC/HTR2A/TAC1/NMB/HTR2B
  4         GO:2000021   Regulation of ion homeostasis                                8.55×10^−7^        AVPR1A/EDNRB/PTPRC/HTR2A/TAC1/IFI6/HTR2B
  4         GO:0007620   Copulation                                                   1.45×10^−6^        AVPR1A/P2RY1/EDNRB/TAC1
  5         GO:0006641   Triglyceride metabolic process                               8.23×10^−5^        ACSL1/DGAT2/PNPLA2/FABP4
  5         GO:0006639   Acylglycerol metabolic process                               8.23×10^−5^        ACSL1/DGAT2/PNPLA2/FABP4
  5         GO:0006638   Neutral lipid metabolic process                              8.23×10^−5^        ACSL1/DGAT2/PNPLA2/FABP4
  5         GO:0019216   Regulation of lipid metabolic process                        1.38×10^−4^        ACSL1/SCD/DGAT2/PNPLA2/LEP
  5         GO:0035337   Fatty-acyl-CoA metabolic process                             1.60×10^−4^        ACSL1/SCD/DGAT2
  6         GO:0072329   Monocarboxylic acid catabolic process                        2.81×10^−4^        ABAT/EHHADH/ALDH3A2/PECR
  6         GO:0006631   Fatty acid metabolic process                                 2.81×10^−4^        PRKAR2B/EHHADH/ALDH3A2/PECR/PDHX
  6         GO:0044282   Small molecule catabolic process                             2.81×10^−4^        ABAT/EHHADH/ALDH3A2/ALDH1B1/PECR
  6         GO:0034308   Primary alcohol metabolic process                            5.03×10^−4^        ALDH3A2/ALDH1B1/PECR
  6         GO:0016054   Organic acid catabolic process                               8.48×10^−4^        ABAT/EHHADH/ALDH3A2/PECR

Only the top five terms are listed. GO, Gene Ontology.

###### 

Kyoto Encyclopedia of Genes and Genomes pathway enrichment for target genes of microRNAs.

  Expression   Cluster             ID         Description                                                  Adjusted P-value   Genes
  ------------ ------------------- ---------- ------------------------------------------------------------ ------------------ ---------------------------
  Up           hsa-miR-103a-2-5p   hsa04921   Oxytocin signaling pathway                                   2.67×10^−2^        NFATC2/OXTR/GUCY1A3/PTGS2
               hsa-miR-582-5p      hsa05167   Kaposi\'s sarcoma-associated herpesvirus infection           2.16×10^−2^        PTGS2/ANGPT2/CXCL2/NFATC2
               hsa-miR-642a-3p     hsa05202   Transcriptional misregulation in cancer                      2.51×10^−2^        NR4A3
               hsa-miR-1292-5p     hsa04625   C-type lectin receptor signaling pathway                     3.91×10^−3^        PTGS2/IRF1
               hsa-miR-1292-5p     hsa05165   Human papillomavirus infection                               1.85×10^−2^        PTGS2/IRF1
               hsa-miR-1292-5p     hsa04923   Regulation of lipolysis in adipocytes                        3.92×10^−2^        PTGS2
               hsa-miR-1292-5p     hsa04370   VEGF signaling pathway                                       3.92×10^−2^        PTGS2
               hsa-miR-1292-5p     hsa04917   Prolactin signaling pathway                                  3.92×10^−2^        IRF1
               hsa-miR-1292-5p     hsa05140   Leishmaniasis                                                3.92×10^−2^        PTGS2
               hsa-miR-1292-5p     hsa05133   Pertussis                                                    3.92×10^−2^        IRF1
               hsa-miR-1292-5p     hsa04657   IL-17 signaling pathway                                      3.92×10^−2^        PTGS2
               hsa-miR-1292-5p     hsa04064   NF-κB signaling pathway                                      3.92×10^−2^        PTGS2
               hsa-miR-1292-5p     hsa04668   TNF signaling pathway                                        4.04×10^−2^        PTGS2
               hsa-miR-1292-5p     hsa05160   Hepatitis C                                                  4.38×10^−2^        IRF1
               hsa-miR-30c-5p      hsa05161   Hepatitis B                                                  2.34×10^−2^        NFATC2/CCNA1/CCNE2
               hsa-miR-30c-5p      hsa04218   Cellular senescence                                          2.34×10^−2^        NFATC2/CCNA1/CCNE2
  Down         hsa-miR-154-3p      hsa00561   Glycerolipid metabolism                                      5.15×10^−3^        GPAM/ALDH1B1
               hsa-miR-154-3p      hsa00340   Histidine metabolism                                         3.86×10^−2^        ALDH1B1
               hsa-miR-154-3p      hsa00053   Ascorbate and aldarate metabolism                            3.86×10^−2^        ALDH1B1
               hsa-miR-154-3p      hsa00410   β-alanine metabolism                                         3.86×10^−2^        ALDH1B1
               hsa-miR-154-3p      hsa00620   Pyruvate metabolism                                          3.86×10^−2^        ALDH1B1
               hsa-miR-25-5p       hsa04514   Cell adhesion molecules (CAMs)                               5.22×10^−4^        PTPRF/F11R/JAM2
               hsa-miR-25-5p       hsa05120   Epithelial cell signaling in Helicobacter pylori infection   4.44×10^−3^        F11R/JAM2
               hsa-miR-25-5p       hsa04670   Leukocyte transendothelial migration                         8.00×10^−3^        F11R/JAM2
               hsa-miR-25-5p       hsa04530   Tight junction                                               1.37×10^−2^        F11R/JAM2
               hsa-miR-25-5p       hsa00340   Histidine metabolism                                         4.01×10^−2^        ALDH1B1
               hsa-miR-302d-3p     hsa04080   Neuroactive ligand-receptor interaction                      1.35×10^−2^        EDNRB/LEP/RXFP1/PTGFR
               hsa-miR-485-3p      hsa04514   Cell adhesion molecules (CAMs)                               3.30×10^−2^        PTPRF/NLGN4X
               hsa-miR-487a-3p     hsa00410   β-alanine metabolism                                         1.07×10^−2^        ALDH1B1/EHHADH
               hsa-miR-487a-3p     hsa00380   Tryptophan metabolism                                        1.07×10^−2^        ALDH1B1/EHHADH
               hsa-miR-487a-3p     hsa00071   Fatty acid degradation                                       1.07×10^−2^        ALDH1B1/EHHADH
               hsa-miR-487a-3p     hsa00280   Valine, leucine and isoleucine degradation                   1.07×10^−2^        ALDH1B1/EHHADH
               hsa-miR-487a-3p     hsa00310   Lysine degradation                                           1.15×10^−2^        ALDH1B1/EHHADH
               hsa-miR-487a-3p     hsa00561   Glycerolipid metabolism                                      1.15×10^−2^        GPAM/ALDH1B1
               hsa-miR-411-3p      hsa00061   Fatty acid biosynthesis                                      3.16×10^−2^        OLAH
               hsa-miR-411-3p      hsa04623   Cytosolic DNA-sensing pathway                                4.34×10^−2^        CXCL10
               hsa-miR-411-3p      hsa04622   RIG-I-like receptor signaling pathway                        4.34×10^−2^        CXCL10
               hsa-miR-411-3p      hsa04657   IL-17 signaling pathway                                      4.34×10^−2^        CXCL10
               hsa-miR-411-3p      hsa04620   Toll-like receptor signaling pathway                         4.34×10^−2^        CXCL10
               hsa-miR-411-3p      hsa04668   TNF signaling pathway                                        4.34×10^−2^        CXCL10

miR, microRNA.

###### 

GO term enrichment for target genes of microRNAs.

  Expression   Cluster             ID           Description                                                                                Adjusted P-value   Genes
  ------------ ------------------- ------------ ------------------------------------------------------------------------------------------ ------------------ --------------------------------------
  Up           hsa-miR-103a-2-5p   GO:0051968   Positive regulation of synaptic transmission, glutamatergic                                1.18×10^−2^        OXTR/NLGN1/PTGS2
               hsa-miR-103a-2-5p   GO:0048661   Positive regulation of smooth muscle cell proliferation                                    1.18×10^−2^        IL10/NR4A3/IL6R/PTGS2
               hsa-miR-103a-2-5p   GO:0050807   Regulation of synapse organization                                                         2.79×10^−2^        OXTR/IL10/NLGN1/ LRRTM2
               hsa-miR-103a-2-5p   GO:0048660   Regulation of smooth muscle cell proliferation                                             2.79×10^−2^        IL10/NR4A3/IL6R/PTGS2
               hsa-miR-103a-2-5p   GO:0048659   Smooth muscle cell proliferation                                                           2.79×10^−2^        IL10/NR4A3/IL6R/PTGS2
               hsa-miR-378a-5p     GO:0007162   Negative regulation of cell adhesion                                                       3.27×10^−3^        IRF1/PELI1/ANGPT2/IL10/SMAD7/SEMA3E
               hsa-miR-378a-5p     GO:0031589   Cell-substrate adhesion                                                                    6.55×10^−3^        LIMS1/RAC2/KIF14/ANGPT2/SEMA3E/PEAK1
               hsa-miR-378a-5p     GO:0050868   Negative regulation of T cell activation                                                   8.67×10^−3^        IRF1/PELI1/IL10/SMAD7
               hsa-miR-378a-5p     GO:1903038   Negative regulation of leukocyte cell-cell adhesion                                        9.77×10^−3^        IRF1/PELI1/IL10/SMAD7
               hsa-miR-378a-5p     GO:0051250   Negative regulation of lymphocyte activation                                               1.53×10^−2^        IRF1/PELI1/IL10/SMAD7
               hsa-miR-582-3p      GO:1902043   Positive regulation of extrinsic apoptotic signaling pathway via death domain receptors    6.49×10^−3^        SKIL/TIMP3
               hsa-miR-582-3p      GO:2001238   Positive regulation of extrinsic apoptotic signaling pathway                               2.23×10^−2^        SKIL/TIMP3
               hsa-miR-582-3p      GO:1902041   Regulation of extrinsic apoptotic signaling pathway via death domain receptors             2.23×10^−2^        SKIL/TIMP3
               hsa-miR-582-3p      GO:0030512   Negative regulation of transforming growth factor β receptor signaling pathway             2.23×10^−2^        SKIL/HTRA4
               hsa-miR-582-3p      GO:1903845   Negative regulation of cellular response to transforming growth factor β stimulus          2.23×10^−2^        SKIL/HTRA4
               hsa-miR-642a-3p     GO:0048839   Inner ear development                                                                      4.66×10^−2^        NR4A3/MCOLN3
               hsa-miR-642a-3p     GO:0043583   Ear development                                                                            4.66×10^−2^        NR4A3/MCOLN3
               hsa-miR-642a-3p     GO:0061469   Regulation of type B pancreatic cell proliferation                                         4.66×10^−2^        NR4A3
               hsa-miR-642a-3p     GO:0061081   Positive regulation of myeloid leukocyte cytokine production involved in immune response   4.66×10^−2^        NR4A3
               hsa-miR-642a-3p     GO:0070486   Leukocyte aggregation                                                                      4.66×10^−2^        NR4A3
               hsa-miR-668-3p      GO:0051983   Regulation of chromosome segregation                                                       1.74×10^−2^        KIF2C/MKI67/GEN1
               hsa-miR-345-5p      GO:0003188   Heart valve formation                                                                      3.30×10^−2^        HEY2/ERG
               hsa-miR-345-5p      GO:0007265   Ras protein signal transduction                                                            4.24×10^−2^        CDC42EP2/NGFR/RASAL2/P2RY8
               hsa-miR-345-5p      GO:0060317   Cardiac epithelial to mesenchymal transition                                               4.65×10^−2^        HEY2/ERG
               hsa-miR-345-5p      GO:0003179   Heart valve morphogenesis                                                                  4.65×10^−2^        HEY2/ERG
               hsa-miR-345-5p      GO:0007266   Rho protein signal transduction                                                            4.65×10^−2^        CDC42EP2/NGFR/P2RY8
               hsa-miR-664a-3p     GO:0060712   Spongiotrophoblast layer development                                                       3.57×10^−3^        LIF/NRK/PHLDA2
               hsa-miR-664a-3p     GO:0010976   Positive regulation of neuron projection development                                       3.11×10^−2^        MAP1B/NTRK2/PAK3/SKIL/NLGN1
               hsa-miR-664a-3p     GO:0033135   Regulation of peptidyl-serine phosphorylation                                              3.11×10^−2^        LIF/PTGS2/NTRK2/RASSF2
               hsa-miR-664a-3p     GO:0010770   Positive regulation of cell morphogenesis involved in differentiation                      3.11×10^−2^        MAP1B/NTRK2/PAK3/SKIL
               hsa-miR-664a-3p     GO:0010769   Regulation of cell morphogenesis involved in differentiation                               3.11×10^−2^        MAP1B/NTRK2/PAK3/SKIL/NLGN1
               hsa-let-7e-5p       GO:0010866   Regulation of triglyceride biosynthetic process                                            5.26×10^−3^        THRSP/DGAT2
               hsa-let-7e-5p       GO:0046890   Regulation of lipid biosynthetic process                                                   5.26×10^−3^        THRSP/SCD/DGAT2
               hsa-let-7e-5p       GO:0019432   Triglyceride biosynthetic process                                                          5.26×10^−3^        THRSP/DGAT2
               hsa-let-7e-5p       GO:0090207   Regulation of triglyceride metabolic process                                               5.26×10^−3^        THRSP/DGAT2
               hsa-let-7e-5p       GO:0046460   Neutral lipid biosynthetic process                                                         5.26×10^−3^        THRSP/DGAT2
               hsa-miR-212-3p      GO:0050708   Regulation of protein                                                                      5.15×10^−3^        SLC2A1/IL1RL1/GPAM/PDE8B
               hsa-miR-212-3p      GO:0002791   Regulation of peptide secretion                                                            5.15×10^−3^        SLC2A1/IL1RL1/GPAM/PDE8B
  Down         hsa-miR-130b-5p     GO:0001101   Response to acid chemical                                                                  2.93×10^−2^        WNT5A/ACSL1/LEP/PTGFR
               hsa-miR-130b-5p     GO:0043032   Positive regulation of macrophage activation                                               2.93×10^−2^        WNT5A/IL1RL1
               hsa-miR-130b-5p     GO:0050727   Regulation of inflammatory response                                                        3.66×10^−2^        WNT5A/LEP/CX3CL1/IL1RL1
               hsa-miR-130b-5p     GO:0072606   Interleukin-8 secretion                                                                    3.66×10^−2^        WNT5A/LEP
               hsa-miR-130b-5p     GO:0001819   Positive regulation of cytokine production                                                 3.66×10^−2^        WNT5A/LEP/CX3CL1/IL1RL1
               hsa-miR-23a-5p      GO:0006865   Amino acid transport                                                                       2.87×10^−2^        LEP/SLC6A6/ATP1A2
               hsa-miR-23a-5p      GO:0051955   Regulation of amino acid transport                                                         2.87×10^−2^        LEP/ATP1A2
               hsa-miR-23a-5p      GO:0006109   Regulation of carbohydrate metabolic process                                               2.87×10^−2^        LEP/IGFBP5/PFKFB4
               hsa-miR-23a-5p      GO:0019229   Regulation of vasoconstriction                                                             2.87×10^−2^        LEP/ATP1A2
               hsa-miR-23a-5p      GO:0046942   Carboxylic acid transport                                                                  2.87×10^−2^        LEP/SLC6A6/ATP1A2
               hsa-miR-23a-5p      GO:0001909   Leukocyte mediated cytotoxicity                                                            3.30×10^−2^        LEP/TREM1
               hsa-miR-23a-5p      GO:0014897   Striated muscle hypertrophy                                                                3.80×10^−2^        LEP/IGFBP5
               hsa-miR-23a-5p      GO:0010906   Regulation of glucose metabolic process                                                    3.80×10^−2^        LEP/IGFBP5
               hsa-miR-23a-5p      GO:0010675   Regulation of cellular carbohydrate metabolic process                                      4.72×10^−2^        LEP/IGFBP5
               hsa-miR-23b-3p      GO:0007422   Peripheral nervous system development                                                      4.39×10^−2^        ALDH3A2/EDNRB/HOXD10
               hsa-miR-302d-3p     GO:0010888   Negative regulation of lipid storage                                                       3.41×10^−2^        LEP/ABCG1
               hsa-miR-302d-3p     GO:0032355   Response to estradiol                                                                      3.41×10^−2^        LEP/TXNIP/PTGFR
               hsa-miR-302d-3p     GO:0008203   Cholesterol metabolic process                                                              3.41×10^−2^        VLDLR/LEP/ABCG1
               hsa-miR-302d-3p     GO:1902652   Secondary alcohol metabolic process                                                        3.41×10^−2^        VLDLR/LEP/ABCG1
               hsa-miR-302d-3p     GO:0006869   Lipid transport                                                                            3.41×10^−2^        VLDLR/LEP/THRSP/ABCG1
               hsa-miR-302d-3p     GO:1900015   Regulation of cytokine production involved in inflammatory response                        3.41×10^−2^        C5orf30/LEP
               hsa-miR-302d-3p     GO:0046890   Regulation of lipid biosynthetic process                                                   3.41×10^−2^        LEP/THRSP/ABCG1
               hsa-miR-302d-3p     GO:0002534   Cytokine production involved in inflammatory response                                      3.41×10^−2^        C5orf30/LEP
               hsa-miR-485-3p      GO:0035384   Thioester biosynthetic process                                                             2.86×10^−2^        PDHX/SCD
               hsa-miR-485-3p      GO:0071616   Acyl-CoA biosynthetic process                                                              2.86×10^−2^        PDHX/SCD

GO, Gene Ontology; miR, microRNA.
